Why and how immunohistochemistry should now be used to screen for the BRAFV600E status in metastatic melanoma? The experience of a single institution (LCEP, Nice, France)

Publisher： John Wiley & Sons Inc

E-ISSN： 1468-3083|29|12|2436-2443

ISSN： 0926-9959

Source： JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol.29, Iss.12, 2015-12, pp. : 2436-2443

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

BRAFV600E and NRASQ61L/Q61R mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting

By  

HISTOPATHOLOGY, Vol. 69, Iss. 4, 2016-10 ,pp. : 680-686

John Wiley & Sons Inc

Access to resources Recommend Favorite

Combining BRAFV600E inhibition with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanoma

By  

EXPERIMENTAL DERMATOLOGY (ELECTRONIC), Vol. 24, Iss. 9, 2015-09 ,pp. : 709-710

John Wiley & Sons Inc

Access to resources Recommend Favorite

Value of immunohistochemistry in the detection of BRAFV600E mutations in fine‐needle aspiration biopsies of papillary thyroid carcinoma

By  

CANCER CYTOPATHOLOGY, Vol. 122, Iss. 1, 2014-01 ,pp. : 48-58

John Wiley & Sons Inc

Access to resources Recommend Favorite

Contiguous verrucous proliferations in syringocystadenoma papilliferum: A retrospective analysis with additional evaluation via mutation‐specific BRAFV600E immunohistochemistry

By  

JOURNAL OF CUTANEOUS PATHOLOGY, Vol. 45, Iss. 3, 2018-03 ,pp. : 212-216

John Wiley & Sons Inc

Access to resources Recommend Favorite

Diffuse melanosis cutis in the setting of BRAFV600E mutant melanoma and treatment with targeted therapies

By  

AUSTRALASIAN JOURNAL OF DERMATOLOGY, Vol. 56, Iss. 2, 2015-05 ,pp. : 128-130

John Wiley & Sons Inc

Access to resources Recommend Favorite